Exact Sciences Corp (NASDAQ: EXAS) started the day on Wednesday, with a price decrease of -4.95% at $57.38, before settling in for the price of $60.37 at the close. Taking a more long-term approach, EXAS posted a 52-week range of $40.62-$79.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 43.88% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 4.59%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -6.89%. This publicly-traded company’s shares outstanding now amounts to $185.05 million, simultaneously with a float of $182.38 million. The organization now has a market capitalization sitting at $10.62 billion. At the time of writing, stock’s 50-day Moving Average stood at $62.31, while the 200-day Moving Average is $58.25.
Exact Sciences Corp (EXAS) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Diagnostics & Research Industry. Exact Sciences Corp’s current insider ownership accounts for 1.46%, in contrast to 99.85% institutional ownership. According to the most recent insider trade that took place on Nov 13 ’24, this organization’s President and CEO bought 19,500 shares at the rate of 51.35, making the entire transaction reach 1,001,325 in total value, affecting insider ownership by 1,074,191. Preceding that transaction, on Oct 08 ’24, Company’s EVP, GM, Precision Oncology sold 929 for 70.00, making the whole transaction’s value amount to 65,030. This particular insider is now the holder of 12,758 in total.
Exact Sciences Corp (EXAS) Earnings and Revenue Records
Exact Sciences Corp’s EPS decrease for this current 12-month fiscal period is -6.89% and is forecasted to reach -0.25 in the upcoming year.
Exact Sciences Corp (NASDAQ: EXAS) Trading Performance Indicators
Let’s observe the current performance indicators for Exact Sciences Corp (EXAS). It’s Quick Ratio in the last reported quarter now stands at 1.93. The Stock has managed to achieve an average true range (ATR) of 2.60. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 3.94. Similarly, its price to free cash flow for trailing twelve months is now 107.89.
In the same vein, EXAS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.17, a figure that is expected to reach -0.33 in the next quarter, and analysts are predicting that it will be -0.25 at the market close of one year from today.
Technical Analysis of Exact Sciences Corp (EXAS)
If we take a close look at the recent performances of Exact Sciences Corp (NASDAQ: EXAS), its last 5-days Average volume was 1.96 million that shows plunge from its year to date volume of 2.62 million. During the previous 9 days, stock’s Stochastic %D was recorded 5.99% While, its Average True Range was 2.48.
Raw Stochastic average of Exact Sciences Corp (EXAS) in the period of the previous 100 days is set at 43.84%, which indicates a major rise in contrast to 2.51% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 37.59% that was lower than 70.78% volatility it exhibited in the past 100-days period.
